Cargando…

Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review

Here, we report two cases of advanced non‐small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shan, Qinge, Wang, Haiyong, Han, Xiao, Guo, Jun, Wang, Zhehai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529576/ https://www.ncbi.nlm.nih.gov/pubmed/32833320 http://dx.doi.org/10.1111/1759-7714.13600

Ejemplares similares

Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study
por: Shan, Qinge, et al.
Publicado: (2019)

A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study
por: Shan, Qinge, et al.
Publicado: (2021)

Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study
por: Shan, Qinge, et al.
Publicado: (2020)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Total lymphocyte count, neutrophil–lymphocyte ratio, and platelet–lymphocyte ratio as prognostic factors in advanced non–small cell lung cancer with chemoradiotherapy
por: Song, Xinyu, et al.
Publicado: (2018)

The appropriate number of ELNs for lymph node negative breast cancer patients underwent MRM: a population-based study
por: Chi, Huiying, et al.
Publicado: (2017)

Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer
por: Song, Xinyu, et al.
Publicado: (2018)

Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review
por: Wang, Haiyong, et al.
Publicado: (2016)

A radiomics nomogram prediction for survival of patients with “driver gene-negative” lung adenocarcinomas (LUAD)
por: Guo, Qi-Kun, et al.
Publicado: (2023)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
por: Song, Xinyu, et al.
Publicado: (2017)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
por: Ma, Xiaoyan, et al.
Publicado: (2016)

Surgical intervention may be a therapeutic option for NSCLC patients with AJCC stage IV: a large population-based study
por: Wang, Haiyong, et al.
Publicado: (2018)

Molecular subtyping of small‐cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies
por: Wang, Haiyong, et al.
Publicado: (2022)

Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: A case report
por: Wang, Ruijuan, et al.
Publicado: (2020)

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
por: Barrett, Michael T, et al.
Publicado: (2017)

Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy
por: Lee, Ho Young, et al.
Publicado: (2022)

Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
por: Liu, Mengyao, et al.
Publicado: (2018)

Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations
por: Hong, Guodai, et al.
Publicado: (2019)

Methylation of N6 adenosine‐related long noncoding RNA: effects on prognosis and treatment in ‘driver‐gene‐negative’ lung adenocarcinoma
por: Yang, Hao‐Shuai, et al.
Publicado: (2022)

PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study
por: Shang, Xiaoling, et al.
Publicado: (2018)

Dishevelled Segment Polarity Protein 3: A Novel Prognosis-related Marker in Pan-driver-gene-negative Lung Adenocarcinoma
por: Cui, Yongmei, et al.
Publicado: (2023)

Immunotherapy in triple-negative breast cancer: A literature review and new advances
por: Valencia, Guillermo Arturo, et al.
Publicado: (2022)

Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives
por: De Mello, Ramon Andrade Bezerra, et al.
Publicado: (2021)

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
por: Fan, Jia-qiao, et al.
Publicado: (2020)

Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer
por: Zhang, Qianqian, et al.
Publicado: (2015)

PRMT6 serves an oncogenic role in lung adenocarcinoma via regulating p18
por: Tang, Jie, et al.
Publicado: (2020)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Single-cell transcriptomics reveals the drivers and therapeutic targets of lymph node metastasis in lung adenocarcinoma
por: Ji, Xin, et al.
Publicado: (2023)

Analysis of Immunotherapy Combined with Radiotherapy in Patients with Brain Metastasis of Driver Gene-Negative Non-Small-Cell Lung Cancer
por: Zhang, Qun, et al.
Publicado: (2022)

Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects
por: Shi, Huan, et al.
Publicado: (2014)

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
por: Carbone, Carmine, et al.
Publicado: (2019)

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients
por: Hu, Guofang, et al.
Publicado: (2016)

Clinical Study on the Efficacy of Bevacizumab in Combination with Pembrolizumab on Cellular Immune Function in the Treatment of Driver Gene-Negative Stage IV Lung Adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer
por: Shi, Huan, et al.
Publicado: (2015)

Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
por: Lou, Yuqing, et al.
Publicado: (2021)

Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity
por: Li, Ming, et al.
Publicado: (2022)

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma
por: Xiang, Luochengling, et al.
Publicado: (2020)

Bevacizumab loaded CalliSpheres® bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma
por: Liu, Haitao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_akignedinkvve6bdhopuejddbs